Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent

CALGARY, Nov. 27 /PRNewswire-FirstCall/ – Oncolytics Biotech Inc. (TSX:
ONC, NASDAQ: ONCY) (“Oncolytics”) today announced that it has been granted
U.S. Patent 7,300,650 entitled “Reovirus for the Treatment of Neoplasia.” The
claims describe methods of using the reovirus to treat cancers that have
inactivated PKR, whether the PKR is inactivated by mutation of Ras or by other
factors. PKR is a host cellular protein responsible for preventing virus
replication within a cell. Tumour cells lacking the activity of PKR are
susceptible to reovirus replication and subsequently, cancer cell killing.

“This patent represents a significant expansion of our intellectual
property portfolio,” said Dr. Matt Coffey, Chief Scientific Officer of
Oncolytics. “The claims cover additional pathways whereby tumours can become
susceptible to reovirus infection and cell death.”

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics. Oncolytics’
clinical program includes a variety of Phase I and Phase II human trials using
REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in
combination with radiation or chemotherapy. For further information about
Oncolytics, please visit www.oncolyticsbiotech.com.

This news release contains forward-looking statements, within the meaning
of Section 21E of the Securities Exchange Act of 1934, as amended.
Forward-looking statements, including among others, the Company’s belief as to
the importance of the issuance of this patent, the safety and efficacy of the
reovirus, the Company’s expectations as to the potential applications of the
patented technology and other statements relating to anticipated developments
in the Company’s business and technologies, involve known and unknown risks
and uncertainties that could cause the Company’s actual results to differ
materially from those in the forward looking statements. Such risks and
uncertainties include, among others, the efficacy of REOLYSIN(R) as a cancer
treatment, the success and timely completion of clinical studies and trials,
uncertainties related to the research and development of pharmaceuticals and
uncertainties related to the regulatory process. Investors should consult the
Company’s quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to
the forward-looking statements. Investors are cautioned against placing undue
reliance on forward-looking statements. The Company does not undertake to
update these forward-looking statements.

SOURCE Oncolytics Biotech Inc.